An observational study in Lung Cancer, Thoracic Cancer and Cancer During Pregnancy, sponsored by Oncology Institute of Southern Switzerland. Recruiting at 4 sites in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.
Sponsored by Oncology Institute of Southern Switzerland · Observational
Among 98 studies in Lung Neoplasms with a site in Switzerland — 26 open to participants now, 32 under way, 11 of them phase 3. Lung Neoplasms · Switzerland.
Among the 98 studies in Lung Neoplasms with a site in Switzerland, this one is the 15th largest by planned enrollment of the 20 observational ones that give a count, is one of 5 that started in 2026, is one of 20 observational ones, reaches primary completion later than 31 of the 31 other live ones, and was the 96th registered.
5,422 studies on the registry are indexed under Lung Neoplasms; 1,346 are open to participants now.
Browse Lung Neoplasms studies →26 of the 98 studies in Lung Neoplasms with a site in Switzerland are open now. Recruiting first, the newest first:
Intuitive Surgical · Sites in Switzerland, Germany, United Kingdom
Ages 18+
Oncology Institute of Southern Switzerland · Sites in Switzerland
Ages 18+
Bristol-Myers Squibb · Sites in Switzerland, United States, Argentina and 22 more countries
Ages 18+
Hoffmann-La Roche · Sites in Switzerland, United States, Argentina and 25 more countries
Ages 18+
Intuitive Surgical · Sites in Switzerland, France, Germany and 1 more country
Ages 18+
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 996 Lung Neoplasms studies recruiting now, 683 (69%) set no upper age limit and 142 (14%) stop at 75 or younger; 45 take children under 18; 142 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
98 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 25 · Phase 3 31 · Phase 4 5
First in 1995; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is below the median of 200 across 1,434 observational studies indexed under Lung Neoplasms.
Median enrollment 136 across the 77 interventional studies, 294 across the 20 observational. Of the 61 that completed or were terminated, 18 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
40 of 98 have an industry lead sponsor. The 10 most frequent:
Oncology Institute of Southern Switzerland is the lead sponsor of 19 studies on the registry; 9 are open to participants now.
Oncology Institute of Southern Switzerland has 2 studies filed under Lung Neoplasms — fewer than ten, so there is no comparison to draw.
6 of the studies in Lung Neoplasms with a site in Switzerland that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05920356Phase 3AmgenA Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) | 2027-06-30 |
| NCT06119581Phase 3Eli Lilly and CompanyA Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer | 2027-11 |
| NCT07099898Phase 3GlaxoSmithKlineA Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301] | 2027-11-05 |
| NCT03979170University Hospital, GenevaPatient-derived Organoids of Lung Cancer to Test Drug Response | 2026-12-30 |
| NCT07398027Carolin SteinackPost-Market Study of Transbronchial Cryo-assisted RFA During Robotic Bronchoscopy With Subsequent Surgical Resection | 2027-03 |
Add all 6 to your calendar (.ics) → With an account.
Among the 98 studies in Lung Neoplasms with a site in Switzerland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The LUCINAE Registry is an international, multicenter observational study collecting data on patients with thoracic cancers (including lung cancer) who are expecting a child. This includes women diagnosed during pregnancy, women who become pregnant during or after cancer, and men receiving cancer treatment at the time their partner conceives.
Because thoracic cancers during pregnancy are rare, there is limited information to guide clinical decisions. This registry aims to describe patient characteristics, diagnostic approaches, treatments, and maternal and fetal outcomes. Data are collected retrospectively and prospectively from participating centers.
The results of this registry are expected to improve understanding of thoracic cancers in this setting and support the development of future clinical recommendations.
The LUCINAE Registry (LUng and thoracic Cancers In pregNAncy rEgistry) is an international, multicenter registry with retrospective and prospective (ambispective) data collection.
The incidence of cancers in younger individuals is increasing, and due to delayed maternal age and other factors, more patients are diagnosed with cancer during pregnancy or become pregnant during or after cancer treatment. Thoracic cancers during pregnancy are rare events, but they are associated with high maternal morbidity and mortality and may have important implications for fetal outcomes.
Currently, there is a lack of specific clinical guidelines for the management of thoracic cancers during pregnancy, and limited data are available regarding the safety and outcomes of anticancer treatments in this setting. Existing registries are not specific for thoracic malignancies, and available evidence is based on a limited number of reported cases.
The LUCINAE Registry aims to collect comprehensive data on biologically female and male patients with thoracic cancers who are expecting a child. The primary objective is to describe clinical and biological characteristics, family history, treatments, and maternal and fetal outcomes.
The study includes two cohorts:
Cohort A (retrospective): patients included after death, with data collected from medical records.
Cohort B (prospective): patients currently treated or diagnosed during the enrollment period, with longitudinal follow-up and periodic data updates.
Eligible participants include women diagnosed with thoracic cancer during pregnancy, women who become pregnant during active disease or within 5 years after treatment, and men receiving active oncological treatment at the time their partner conceives.
Data collected include patient characteristics (demographics, medical history, genetic information), tumor characteristics (stage, histology, biomarker status), diagnostic procedures, treatment details (including systemic therapies, surgery, and radiotherapy), pregnancy characteristics, complications, and maternal and fetal outcomes. Follow-up data are collected at multiple timepoints up to 5 years after delivery, when available.
Analyses will be primarily descriptive and will evaluate clinical and biological characteristics, treatment patterns, and outcomes. Correlation analyses between treatments and outcomes will also be performed. The study does not impose any intervention, and all treatment decisions are made by the treating physicians.
The registry is intended to improve understanding of thoracic cancers in the context of pregnancy, to support future research, and to contribute to the development of clinical management strategies for this patient population.
The study will include all pregnant biological female patients, of any ethnicity, with a diagnosis of thoracic cancer at any stage and men with a diagnosis of thoracic cancer who were undergoing active oncological treatment at the time their partner conceived their child.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
1. All patients with a diagnosis of thoracic cancer (including lung cancer, mesothelioma, thymic epithelial tumors, neuroendocrine tumors or sarcoma of the thorax and other rare thoracic entities) and pregnancy (positive pregnancy test) including:
Exclusion Criteria:
Retrospective patients: patients who are included in the registry only after death.
Prospective patients: patients who are currently treated at the participating site or will be diagnosed during the enrollment
Timing of diagnosis
Timing of cancer diagnosis with respect to the onset of pregnancy.
Time frame: At the moment of patient enrolment
Modality of diagnosis
Method used for cancer diagnosis.
Time frame: At the moment of patient enrolment
Duration of treatment
Duration of the treatment received during the pregnancy
Time frame: Throughout study participation, up to 5 years after delivery.
Maternal outcome
Survival of the mother at the end of gestation.
Time frame: At the conclusion of pregnancy.
Fetal outcome
Survival of the fetus at the end of gestation.
Time frame: At the conclusion of pregnancy.
Parental overall survival
Overall survival of biologically female and male thoracic cancer patients included in the registry, defined as time from thoracic cancer diagnosis to death from any cause.
Time frame: From thoracic cancer diagnosis until 5 years after delivery.
Offspring's overall survival
Overall survival of the offspring of enrolled parents, defined as time from birth to death from any cause.
Time frame: From birth until 5 years after birth.
Pregnancy complications
Incidence of complications associated with the pregnancy.
Time frame: From pregnancy diagnosis to 1 month after delivery.
Gestational age at delivery
Gestational age of the fetus at the moment of delivery.
Time frame: At the conclusion of pregnancy.
Congenital abnormalities
Proportion of newborns diagnosed with congenital abnormalities.
Time frame: From birth to 30 days after birth.
Neonatal intensive care unit (NICU) admission
Proportion of newborns admitted to neonatal intensive care unit after birth.
Time frame: From birth to 30 days after birth.
Apgar score
Measurement of Apgar score to assess the newborn's vital signs and immediate need for medical intervention.
Time frame: Measured 1 minute and 5 minutes after birth.
Oncologic treatment exposure
Type, timing, and toxicity of anticancer treatments administered during and after pregnancy.
Time frame: Throughout pregnancy until 5 years after delivery.
Started Apr 2026 (actual). Primary completion is estimated for Dec 2035, 116 months after the start.
Of 591 non-industry observational studies under Lung Neoplasms, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 162. This study's planned 116 months is above that.
Counting every sponsor, half of 681 studies reached it within 57 months; a quarter within 25 and three quarters within 135.
Start moved once since we started tracking on Sep 25, 2026: Jun 2026 → Apr 2026, on Oct 21, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Oncology Institute of Southern Switzerland